Skip to main content

Table 3 Secondary preventive drug use at dischargea

From: Usage of PCI and long-term cardiovascular risk in post-myocardial infarction patients: a nationwide registry cohort study from Finland

 

Group 1

Group 1 b

Group 2

N of patients

32,909

7034

25,875

OAP

17,056 (51.8%)

2318 (33.0%)

14,738 (57.0%)

Beta-blocker

24,119 (73.3%)

4341 (61.7%)

19,778 (76.4%)

Statin

22,123 (67.2%)

3387 (48.2%)

18,736 (72.4%)

ACE inhibitor or ARB

18,663 (56.7%)

3167 (45.0%)

15,496 (59.9%)

Number of secondary preventive drugs

 0

4221 (12.8%)

1644 (23.4%)

2577 (10.0%)

 1

4284 (13.0%)

1428 (20.3%)

2856 (11.0%)

 2

6497 (19.7%)

1548 (22.0%)

4949 (19.1%)

 3

9069 (27.6%)

1434 (20.4%)

7635 (29.5%)

 4

8838 (26.9%)

980 (13.9%)

7858 (30.4%)

 mean (+/−sd)

2.4 (1.3)

1.8 (1.4)

2.6 (1.3)

 range (min; max)

0.0; 4.0

0.0; 4.0

0.0; 4.0

 median (Q1; Q3)

3.0 (1.0; 4.0)

2.0 (1.0; 3.0)

3.0 (2.0; 4.0)

  1. a(prescription filled within 30 days for new users and within 90 days for old users)
  2. Abbreviations: ACE, angiotensin-converting enzyme; ARB angiotensin receptor blocker; OAP, oral antiplatelet; Q, quartile; sd, standard deviation